Shionogi has inked an exclusive promotion accord with Spanish drug maker Ferrer for its opioid-induced constipation (OIC) treatment Rizmoic (naldemedine) in Spain, the Osaka-based company said on June 19. Rizmoic was approved by the European Commission in February for the…
To read the full story
Related Article
- Shionogi in Marketing Tie-Up with Molteni for Rizmoic
May 23, 2019
- Shionogi Grabs European Nod for Naldemedine
February 25, 2019
BUSINESS
- Leqembi FY2025 Global Sales Reach 88 Billion Yen: Eisai
May 1, 2026
- Rohto Files CMV Corneal Endotheliitis Drug in Japan
May 1, 2026
- Mochida Files in Japan for PAH Drug Tyvaso DPI
May 1, 2026
- Tanabe Clinches EU Approval for Parkinson’s Drug Onerji
May 1, 2026
- 3D “Deeply Disappointed” by Toho Plan to Seek Defense Trigger Approval
May 1, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





